Regulatory & Procedural Update
Factual Note: While Dr. Benjamin Caplan and The Commonwealth Project were formally accepted and designated by the DEA Administrative Law Judge as official participants to provide expert clinical testimony representing older adult healthcare during proposed federal Schedule III rescheduling proceedings, the scheduled administrative hearings did not convene due to subsequent agency postponements, legal challenges, and administrative delays. Dr. Caplan continues to actively advise federal policymakers and advocate for statutory reform to ensure safe, Medicare-integrated therapeutic access for seniors.
Policy Answer: Dr. Caplan’s DEA rescheduling testimony prepared on behalf of The Commonwealth Project addresses the clinical necessity of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). The clinical position emphasizes that cannabis possesses accepted medical use for chronic pain, neuropathy, and insomnia, while transferring it to Schedule III eliminates 280E tax burdens, accelerates clinical research, and establishes pathways for Medicare and private insurance coverage to reduce geriatric polypharmacy.
Federal regulatory analysis, health economics modeling, and clinical policy advocacy under the Controlled Substances Act.
The effort to reschedule cannabis under the federal Controlled Substances Act (CSA) represents the most significant proposed realignment of federal drug policy in more than half a century. When the U.S. Drug Enforcement Administration (DEA) initiated formal administrative proceedings regarding the Department of Justice’s proposed rule to transfer cannabis from Schedule I to Schedule III, The Commonwealth Project—under my clinical leadership as Chief Medical Officer—was formally selected and designated by the DEA Administrative Law Judge as an accepted participant to provide expert clinical testimony.
1. The Clinical Imperative: Why Schedule I Classification Is Scientifically Indefensible
Under 21 U.S.C. § 812, Schedule I is legally reserved exclusively for substances that have “no currently accepted medical use in treatment in the United States” and a “lack of accepted safety for use under medical supervision.” From the standpoint of clinical medicine, maintaining cannabis in Schedule I has long been an evidence-free anachronism:
- Accepted Medical Utility: More than 38 U.S. states operate comprehensive, state-regulated medical cannabis programs where millions of certified patients receive physician-guided treatment for chronic pain, epilepsy, multiple sclerosis spasticity, and chemotherapy-induced nausea.
- Safety Under Medical Supervision: Across my career overseeing more than 350,000 patient evaluations, cannabinoids demonstrate an exceptionally favorable therapeutic index compared to Schedule II pharmaceuticals such as fentanyl, oxycodone, and amphetamines. Cannabinoid receptors (CB1) are absent from the brainstem cardiorespiratory drive centers, rendering fatal respiratory overdose virtually impossible.
- The FDA and HHS Scientific Review: In its landmark 250-page scientific evaluation, the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) formally concluded that cannabis has verifiable medical efficacy for pain and nausea and recommended Schedule III reclassification under the statutory Eight-Factor Analysis.
| Statutory Criteria | Schedule I (Current Status) | Schedule III (Proposed Reform) | Real-World Clinical Impact |
|---|---|---|---|
| Accepted Medical Use | Statutorily Defined as None | Formally Recognized by Federal Law | Removes federal medical malpractice and research barriers for clinicians |
| Clinical Research Access | Burdensome Schedule I DEA registration & NIDA monopoly | Standard academic clinical trial protocols | Allows U.S. academic medical centers to conduct large-scale RCTs |
| Healthcare & Insurance Integration | Total exclusion from Medicare & commercial health plans | Pathway for Medicare Advantage demonstration models | Subsidizes physician consultations for low-income seniors on fixed incomes |
| Internal Revenue Code § 280E | Applies (No standard business deduction) | Does NOT Apply to Schedule III substances | Lowers consumer retail costs by ending punitive tax penalties on operators |
2. The Commonwealth Project Mission: Prioritizing Senior Healthcare in Federal Policy
The Commonwealth Project was founded specifically to advocate for the health and financial wellbeing of older Americans—the fastest-growing demographic of medical cannabis users in the nation. As I detailed in our clinical framework:
- Combating the Geriatric Polypharmacy Epidemic: Over 30% of Americans aged 65 and older are prescribed five or more daily medications. As outlined in my analysis of medical cannabis for seniors, replacing high-risk medications like opioids and benzodiazepines with physician-guided cannabinoids prevents thousands of fall-related hospitalizations and fatal overdoses each year.
- Equipping Congressional Leadership with Objective Science: Prior to the scheduled proceedings, we ensured that leadership in both the U.S. Senate and the House of Representatives received copies of my medical textbook, The Doctor-Approved Cannabis Handbook (Penguin Random House). Educating lawmakers with peer-reviewed physiology is the only way to replace political soundbites with compassionate, evidence-based legislation.
3. What Happened to the DEA Rescheduling Hearings?
Following the formal selection of accepted testifiers in late 2024, the scheduled administrative hearings faced procedural delays, legal maneuvers by prohibitionist advocacy groups, and administrative postponements by the agency. Consequently, the public evidentiary hearings were stayed and did not convene.
However, the underlying scientific determination remains unassailable: the Department of Health and Human Services has formally recommended Schedule III classification, grounded in an exhaustive medical review. While federal administrative machinery moves slowly, clinical care cannot wait. At CED Clinic and across our digital health initiatives, we continue to deliver evidence-grounded consultations, research-backed titration protocols, and patient-centered advocacy every single day.
Frequently Asked Questions: DEA Rescheduling & The Commonwealth Project
Did the DEA rescheduling hearings with Dr. Caplan take place?
No. While Dr. Benjamin Caplan and The Commonwealth Project were officially accepted as designated participants to provide clinical testimony, the scheduled administrative hearings did not convene due to procedural stays and federal administrative delays.
What is the primary difference between Schedule I and Schedule III?
Schedule I drugs (like heroin) are defined as having no accepted medical use and high abuse potential. Schedule III drugs (like ketamine, anabolic steroids, and Tylenol with codeine) have recognized medical uses, moderate to low physical dependence liability, and can be legally prescribed under federal law.
Would moving cannabis to Schedule III legalize it nationally?
Rescheduling to Schedule III does not automatically create a commercial adult-use recreational market. Instead, it formally legalizes medical use under federal prescription frameworks, eliminates the punitive 280E tax code on businesses, and dramatically expands academic clinical research.
How would Schedule III rescheduling affect Medicare patients?
Under Schedule III, cannabis transitions into an officially recognized medicine, allowing Medicare Advantage plans and private insurers to develop demonstration coverage models for clinician consultations and prescription cannabinoid products, easing financial burdens on seniors.
What role did The Commonwealth Project play in the DEA proceedings?
The Commonwealth Project participated as an officially designated organizational participant, representing the healthcare interests of older adults and advocating for integrating medical cannabis into mainstream geriatric care.
Where can I learn more about Dr. Caplan’s federal policy work?
You can explore Dr. Caplan’s executive perspectives on The Commonwealth Project initiative, review his writings in The Doctor-Approved Cannabis Handbook, or visit CED Clinic.
Written & Medically Reviewed by Benjamin Caplan, MD
ABFM Board-Certified Family Physician | MA Medical License #240562 | NPI: 1962722637
Chief Medical Officer, The Commonwealth Project & CED Clinic | Author of The Doctor-Approved Cannabis Handbook
Dr. Benjamin Caplan has evaluated over 350,000 patients across his career, advising state health departments, federal policymakers, and healthcare systems on evidence-based cannabis reform. For clinical consultations or advisory inquiries, visit CED Clinic or explore The Commonwealth Project.
